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Abstract
Oversulfated chondroitin sulfate (OSCS) was identified as a contaminant in certain heparin
preparations as the cause of adverse reactions in patients. OSCS was found to possess
both plasma anticoagulant activity and the ability to activate prekallikrein to kallikrein. Differ-
entially sulfated chondroitin sulfates were prepared by synthetic modification of chondroitin
sulfate and were compared to the activity of OSCS purified from contaminated heparin.
Whilst chondroitin sulfate was found to have minimal anticoagulant activity, increasing sulfa-
tion levels produced an anticoagulant response which we directly show for the first time is
mediated through heparin cofactor II. However, the tetra-sulfated preparations did not pos-
sess any higher anticoagulant activity than several tri-sulfated variants, and also had lower
heparin cofactor II mediated activity. Activation of prekallikrein was concentration dependent
for all samples, and broadly increased with the degree of sulfation, though the di-sulfated
preparation was able to form more kallikrein than some of the tri-sulfated preparations. The
ability of the samples to activate the kinin system, as measured by bradykinin, was observed
to be through kallikrein generation. These results show that whilst an increase in sulfation of
chondroitin sulfate did cause an increase in anticoagulant activity and activation of the kinin
system, there may be subtler structural interactions other than sulfation at play given the dif-
ferent responses observed.
Introduction
In 2008 there were many adverse events, including fatalities, associated with the administra-
tion of certain preparations of heparin [1]. Analysis of the heparin preparations associated
with these events found a contaminating material, oversulfated chondroitin sulfate (OSCS)
[2]. This contaminating material was found to interact with the contact system in plasma
through activation of prekallikrein [3] which cleaved high molecular weight kininogen, leading
to the formation of bradykinin [4]. Bradykinin is a potent vasodilator which causes a hypoten-
sive response, and has been proposed to be the most likely cause of death in numerous patients
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who were infused with contaminated heparin preparations [5]. Animal studies using rats and
pigs have shown that OSCS can cause a marked drop in blood pressure that could be prevented
by administration of a bradykinin receptor antagonist [3, 5, 6]. This indicates that activation of
the kinin system leading to generation of bradykinin is the likely mechanism of action of the
adverse effects seen with OSCS contaminated heparin.
Structural analysis of OSCS purified from contaminated heparin preparations showed that
chondroitin sulfate (CS) had been subjected to chemical oversulfation to increase the number
of sulfates to four on the main disaccharide unit [2]. Furthermore, detailed characterization
showed that OSCS has O-sulfates at the 4 and 6 positions on N-acetylgalactosamine, and posi-
tions 2 and 3 on glucuronic acid [2]. This contrasts with native chondroitin-4- sulfate and
chondroitin-6-sulfate which are predominantly sulfated only at position 4 or position 6 of N-
acetylgalactosamine respectively [2, 6]. An increase in the degree of sulfation can increase the
anticoagulant activity of chondroitin sulfate [7, 8] and the anticoagulant effect was observed in
normal human plasma, and plasma depleted of antithrombin [9]. This is in agreement with
previous reports that highly sulfated chondroitin sulfates [10, 11] have an anticoagulant action
in plasma and it has been proposed to be primarily through potentiation of heparin cofactor II
(HCII). The limitation of all these studies is the use of imprecise assay systems from which
anticoagulant activity through HCII is inferred, and the assumption that binding interaction
between OSCS and HCII indicates the potentiation of HCII inhibition of thrombin. The
assumption that anticoagulant activity is solely through HCII [9] in antithrombin deficient
plasma ignores other known mechanisms which heparin, and therefore perhaps OSCS, can act
through, and these include potentiation of tissue factor pathway inhibitor on factor Xa [12] or
protein C inhibitor on thrombin and factor Xa [13].
The current study aims were to determine: the specific activities of differentially sulfated
chondroitin sulfates by multiple anticoagulant methods, with a particular focus on heparin
cofactor II activity; to investigate the correlation between the degree and sulfation pattern with
anticoagulant activity of OSCS; and to measure the effect that increasing the sulfation of chon-
droitin sulfates has on prekallikrein activation and whether generation of bradykinin by OSCS
is associated with production of kallikrein.
Materials and methods
Materials
Synthetic oversulfated chondroitin sulfates were prepared from chondroitin sulfate A (Sigma
Aldrich, Italy) as previously described by use of pyridine–sulfur trioxide complex in dimethyl-
formamide [2]. The sample of OSCS isolated from contaminated heparin was a gift from Leo
Pharma (Cork, Ireland). Chrondroitin-4- sulfate (from bovine trachea) and dextran sulfate
(from Leuconostoc spp.) were obtained from Sigma, UK. The 5th International Standard for
Unfractionated Heparin, 97/578, human thrombin and human antithrombin preparations for
potency assays and a separate antithrombin for the fluorescence titration assay were from
NIBSC (Potters Bar, UK). Sheep and human plasma for clotting assays were purchased from
First Link, UK and National Blood Transfusion Service, UK, respectively. Activated Partial
Thromboplastin Time (APTT) reagents were Actin-FS from Sysmex, UK and APTT-SP from
Werfen, UK. Bovine activated factor X was from Diagnostic Reagents, UK. Human heparin
cofactor II was from Enzyme Research, UK. Chromogenic substrates S2302, S2238 and S2765
were from Werfen, UK. Pooled normal human plasma for prekallikrein and bradykinin assays
was obtained from George King, Kansas USA. The Bradykinin ELISA kit was obtained from
Enzo Research, Exeter, UK. All other reagents were analytical grade and obtained from Sigma,
UK.
Effect of sulfation on CS anticoagulant activity and kinin activation
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Methods
NMR experimental procedure. Proton and HSQC-NMR spectra were obtained at 500
MHz with a Bruker Avance 500 spectrometer equipped with a 5-mm TXI probe. Chemical
shift values were measured downfield from trimethylsilyl propionate sodium salt (TSP) as
standard at 40˚C and the offset was set at the residual water resonance. Samples (10 mg) were
previously submitted to a double lyophilisation from D2O and finally dissolved in 0.6 ml of
deuterium oxide (99.996 at% D2O). Mono-dimensional
1H spectra were obtained with pre-sat-
uration of residual HDO, 128 scans, and a recycle delay of 10 s. Two-dimensional gradient
enhanced HSQC-NMR spectra were recorded via double inept transfer with a carbon decou-
pling (garp4) during acquisition using a sensitivity improvement trim pulses in inept transfer
and shaped pulses for all 180˚ pulses on 13C channel (hsqcetgsisp2.2 Bruker sequence) with
512 increments of 64 scans each. The polarization transfer delay (D = 1/[2 1JC–H]) was set with
1JC–H coupling values of 139–150–170 Hz. The matrix size 1K x 512 was zero filled to 4K x 2K
by application of a squared cosine function prior to Fourier transformation. Integration of
cross-peaks was made using standard Bruker XWINNMR 3.5 software.
Degree of sulfation. Integration of heteronuclear single quantum coherence (HSQC-
NMR) spectra was validated for determination of compositional analysis of heparins and
applied to chemically modified glycosaminoglycan samples. The relative molar percentages of
6-OSO3, 4-OSO3 groups for galactose amine residues and of non-sulfated, 2,3-OSO3, 2-OSO3,
and 3-OSO3 groups for glucuronic acid residues was evaluated from the integration of the cor-
responding volumes of their anomeric signals (see Table A and Fig A in S1 File).
Molecular weight determination. Molecular weight determinations were performed by
HPSEC- TDA on a Viscotek (Houston, Texas) instrument equipped with a VE1121 pump,
Rheodyne valve (100 μl), and triple detector array 302 equipped with refraction index (RI), vis-
cometer, and light-scattering (90˚ and 7˚) systems [14] for synthetic OSCS samples only.
Molecular weights for all samples were also determined by the USP broad standard method
for molecular weight calibration of Unfractionated Heparin, adapted from the USP mono-
graph for Heparin Sodium [15].
Anticoagulant assays. The test samples were assayed against the 5th International Stan-
dard for unfractionated heparin using an automated coagulometer (ACL-TOP 500, Instru-
mentation Laboratories, UK). Concentration response curves, with at least 3 dilutions and
replicates for both standard and test were assayed within each run. Potency estimates and sta-
tistical analysis of data were carried out in accordance with European Pharmacopoeia guide-
lines [16], using CombiStats 5.0 (European Directorate of the Quality of Medicine, (EDQM),
France). Apart from the human plasma assay which was analysed using a slope ratio model, all
other assays were analysed using a parallel line bioassay model. These analysis methods use
multiple dilutions which estimate the activity of a sample relative to the standard used and
allow for an assessment of model validity by ANOVA i.e. linearity and common intercept for
slope ratio model, linearity and parallelism for the parallel line model. This is the recom-
mended method of potency assignment according to EDQM guidelines (16). The specific
activity in IU/mg was calculated from the potency obtained by each assay method relative to
the dry weight of the test sample.
Sheep-plasma assay: A modified version of the previous European Pharmacopeia assay [17]
based on the APTT, using sheep plasma was carried out. This method was adapted to be car-
ried out on an automated coagulometer. Briefly, samples were prepared in tris-buffered saline
(TRIS 50mM, NaCl 150mM, pH 7.4) and each dilution was mixed with sheep plasma before
addition of Actin-FS, the APTT reagent. After incubation, clotting was started by addition of
calcium chloride and the clotting time recorded.
Effect of sulfation on CS anticoagulant activity and kinin activation
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Human-plasma assay: This plasma based APTT assay was performed in a similar manner
as the sheep plasma assay. The samples were diluted, mixed with human plasma and clotting
times were recorded following the addition of APTT-SP (APTT reagent), and calcium chloride
as recommended by the manufacturer.
Anti-Xa and anti-IIa assays: The methods used were modified from the method as
described in the United States Pharmacopoeia (USP) general monograph for Assay of Heparin
(USP Monograph, General Chapter 208). The methods were modified for use on an automated
coagulometer.
Heparin cofactor II assay: Samples were diluted with tris buffered saline, and mixed 1-to-1
with heparin cofactor II (2.5μg/ml). Human thrombin (1 IU/ml) was added to the mixture and
incubated for 420 seconds prior to addition of chromogenic substrate specific for thrombin
(S2238, 1mM). The change in colour was recorded at 405nm.
Kallikrein generation assay. The test compounds were dissolved in distilled water and a
dilution series was made using a low salt buffer (50mM TRIS, 14mM NaCl pH 7.8). Each sam-
ple was mixed with an equal amount of pooled normal plasma prior to incubation at 37˚C.
The blank control with pooled normal plasma was found to give no kallikrein activity. Experi-
ments found that a five-minute incubation between sample and plasma provided maximal kal-
likrein formation (data shown in Table B in S1 File). The samples were then incubated for five
minutes, prior to addition of chromogenic substrate (S2302, 0.5mM) and colour was devel-
oped for four minutes before stopping the assay using 50% acetic acid. The reaction samples
were read at 405nm with a 490nm reference reading subtracted. The amount of kallikrein gen-
erated is proportional to the amount of chromogen yielded. Due to the absence of reference
materials for this assay, dextran sulfate which is known for its ability to cause the activation of
prekallikrein [18] was used as a positive control.
Bradykinin generation assay. Samples were prepared as described in the kallikrein gener-
ation assay. Following the five minute incubation time between test compound and normal
pooled plasma, samples were diluted 10 fold with ice cold ethanol (as described in the com-
mercial Bradykinin ELISA kit, Enzo Research, Exeter, UK) and stored on melting ice for 1
hour [4]. Samples were centrifuged at 10,000g for 5 minutes, the supernatant was collected and
dried using a rotary evaporator and stored -40˚C. Bradykinin was measured following the
method as described in the commercial ELISA Kit.
Antithrombin titration assay. Measurement of the ability of each oversulfated chondroi-
tin sulfate material to bind to antithrombin was assessed using an antithrombin titration assay
[19]. Briefly, a concentration range 5 to 100μg/ml of each sample was prepared in buffer
(50mM TRIS, 150nM NaCl, 10 mM EDTA, 0.05% Tween-20, pH 7.4). The concentrations for
each sample (100μl) were mixed with 100μl purified antithrombin (NIBSC, South Mimms
UK) and the increase in fluorescence (λEX 280 nm, λEM 340 nm) over antithrombin alone was
recorded.
Results
Physicochemical analysis
Six differentially sulfated samples of CS were prepared. Table 1 shows the sulfation patterns of
different preparations of over sulfated chondroitin sulfates. The degree of sulfation ranged
from 2.4 to 4.0. Percentage distribution of sulfate groups per residue was evaluated by 1H/13C
NMR correlation experiments. Spectra with assignments are reported in supplementary mate-
rial (Fig A and Fig B in S1 File). In all cases, with the exception of the disulfated chondroitin
sulfate with 90% GalNAc6S, the galactosamine was fully sulfated by comparison with native CS
(Table 1). For the tri-sulfate and tetra-sulfate samples the further increase in overall sulfation
Effect of sulfation on CS anticoagulant activity and kinin activation
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was at glucuronic acid carbon-2 and carbon-3. For the three tri-sulfated samples (3.0, 3.1 and
3.2 sulfates), the key difference is more carbon-2 and -3 in the glucuronic acid being sulfated
(25%, 28% and 35%).
The molecular weights were measured by two different methods. The first method used a
triple detector array (TDA) calibrated with samples of known weight average molecular weight
(Mw), polydispersity and intrinsic viscosity [14], and the second method used a broad stan-
dard calibrant (the USP Heparin Sodium Molecular Weight Calibrant, F0L483), an unfractio-
nated heparin sample of defined molecular weight distribution [15]. The two different
analytical approaches obtained different number average (Mn) and weight average (Mw)
molecular weights, with the TDA calculating higher Mn and Mw than the broad standard
method (Table 2).
The molecular weights of the preparations were measured and compared to OSCS purified
from contaminated heparin preparations against the USP Heparin Sodium Molecular Weight
Calibrant (Table 2). All the semi-synthetically prepared samples had molecular weights (Mw)
higher than purified OSCS (Mw range 17600 to 21960 compared to 15740); however, the poly-
dispersity was broadly comparable for all samples (range 1.3 to 1.4).
Anticoagulant assays
Table 3 shows the anticoagulant activity of all the OSCS samples and a unadulterated heparin
sample relative to the 5th IS for unfractionated heparin. Apart from the CS-A sample, all
Table 1. Sulfation pattern (%) of different preparations of OSCS.
Glucuronic Acid Galactosamine
Disaccharide Sulfation degree G2S,3S G2S G3S G GalNAc4S GalNAc6S
CS 1.0 (native CS) 0 0 0 100 70 30
CS 2.4 18 5 10 67 100 90
CS 3.0 25 41 12 22 100 100
CS 3.1 28 42 12 17 100 100
CS 3.2 35 42 12 11 100 100
CS 4.0 100 0 0 0 100 100
CS 4.0 #2 100 0 0 0 100 100
Level of sulfation indicated for each sample on carbon 2 and/or 3 in glucuronic acid, and on carbon 4 and 6 in galactosamine via NMR HSQC quantitative analysis.
https://doi.org/10.1371/journal.pone.0193482.t001
Table 2. Molecular weights of additionally sulfated CSs. Molecular weights have been measured via HP-SEC/ TDA.
Via HP-SEC/TDA USP Broad Standard Method
Mn Mw PD Mn Mw PD
CS 2.4 13400 31100 1.6 12680 17600 1.4
CS 3.0 19900 28000 1.4 14980 21050 1.4
CS 3.1 21780 28560 1.3 16280 21960 1.4
CS 3.2 18400 23800 1.3 15860 21390 1.4
CS 4.0 29200 35100 1.2 16360 21100 1.3
CS 4.0 #2 30100 35700 1.2 16820 21750 1.3
Isolated OSCS - - - 11480 15740 1.4
For the purified OSCS sample the molecular weight was calibrated against USP Heparin Sodium Molecular Weight Calibrant (F0L483). Mn = number average
molecular weight; Mw = weight average molecular weight; PD = Polydispersity (Mw/Mn).
https://doi.org/10.1371/journal.pone.0193482.t002
Effect of sulfation on CS anticoagulant activity and kinin activation
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samples gave statistically valid results by slope ratio analysis in the human plasma assay and by
parallel line analysis for all other assays. Validity assessment was by ANOVA [16] using Com-
biStats which was considered to confirm that samples gave a linear dose response across the
doses used, had a common intercept in the by slope ratio model or parallel dose-response rela-
tionships in the parallel line model. The heparin sample included gave anticoagulant activity
values which were similar across all the methods used. Native CS had no measurable anticoag-
ulant activity in either plasma based or anti-Xa and anti-IIa assays. Specific activity for the
samples by the anti-Xa and anti-IIa assays were all below 5 IU/mg, indicating that these sam-
ples could not potentiate the inhibitory action of antithrombin to a high degree. Both synthetic
and purified oversulfated CSs expressed relatively high anticoagulant activity in plasma based
clotting assays. With the exception of CS2.4 which gave similar activity in both types of assay,
all other OSCS showed 3–8-fold higher activity in the sheep plasma assay than in the human
plasma method. There was no apparent correlation between degree of sulfation and the antico-
agulant activity in plasma-based assays. In the heparin cofactor II mediated assay, the 3 tri-
Table 3. Anticoagulant activities of chemically sulfated CSs and purified OSCS from contaminated heparin.
IU/mg (95% Confidence Limits)
sulfate level / disaccharide Human APTT Sheep APTT Anti-Xa Anti-IIa HCII
CS 2.4 16 (15–17) 41 (40–42) <1 <1 152 (134–173)
CS 3.0 52 (50–54) 129 (126–132) 1.4 (1.2–1.6) 3.1 (2.9–3.3) 753 (662–858)
CS 3.1 55 (54–56) 141 (137–144) 1.6 (1.4–1.8) 4.2 (3.9–4.5) 906 (796–1032)
CS 3.2 52 (50–54) 138 (126–132) 2.0 (1.8–2.2) 3.7 (3.3–4.3) 898 (788–1022)
CS 4.0 48 (47–49) 137 (134–140) 5.3 (4.8–5.9) 4.5 (3.9–5.3) 324 (259–404)
CS 4.0 (#2) 50 (49–51) 142 (139–145) 5.9 (5.3–6.6) 3.8 (3.5–4.0) 264 (212–330)
Purified OSCS from Contaminated Heparin 56 (54–57) 181 (174–189) 5.7 (5.2–6.3) 4.9 (4.7–5.1) 187 (166–210)
Chondroitin 4 sulfate <1 <1 <1 <1 1.9 (1.8–2.1)
Heparin sample 209 (191–229) 226 (219–233) 214 (207–221) 209 (196–223) 241 (223–261)
Values are IU/mg estimated against the 5th International Standard for unfractionated heparin (NIBSC, 97/578), with 95% confidence limits in brackets. All results were
considered valid using multiple dilution models–slope ratio for plasma (human and sheep) assays and parallel line for purified protein (antithrombin, anti-IIa, anti-IIa,
HCII anti-IIa) assays.
https://doi.org/10.1371/journal.pone.0193482.t003
Fig 1. Kallikrein generation in normal pooled plasma by synthetic and purified OSCSs, native chondroitin sulfate,
dextran sulfate and unfractionated heparin. Error bars = standard deviations (SD), n = 6, note lines for native CS,
unfractionated heparin and plasma alone are overlapping. Inset chart shows line (. . ..) indicating Δ0.2 OD above
baseline used to select concentration of samples for the bradykinin assay.
https://doi.org/10.1371/journal.pone.0193482.g001
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sulfated CSs gave three-fold higher activities than the tetra- and di-sulfated CSs, showing that
an increase in sulfation would not necessarily result in higher activity. Overall, the synthetic
tetra-sulfated material (CS4.0) has a very similar anticoagulant profile to the purified OSCS.
Samples were all incubated with thrombin or factor Xa only and found to have no direct
inhibitory action on either enzyme with results similar to buffer only.
Kallikrein generation
Fig 1 summarises the concentration dependency of kallikrein generation for all the samples.
Both native CS and unfractionated heparin did not generate kallikrein at any of the concentra-
tions tested, with results very similar to plasma alone. In contrast, all over-sulfated CSs were
able to generate kallikrein, in a concentration dependent manner. The di- and tri-sulfated CSs
gave a similar concentration response profile, whilst the synthetic tetra CS and the purified
OSCS exhibited higher activity especially at lower concentrations (<20μg/ml).
Bradykinin generation
It has been shown that OSCS can lead to the generation of bradykinin [4], but it has not been
shown that OSCS triggered kallikrein activity leads to bradykinin production. While it is rea-
sonable to assume that this mechanism will lead to some bradykinin production, it is possible
that the OSCS samples might also induce bradykinin through other, non-kallikrein associated
routes. To investigate the link between kallikrein and bradykinin production a single concen-
tration of each sample was used. A concentration which generated a 0.2 optical density change
(See Fig 1, inset) in the kallikrein assay was chosen (Table 4). On the basis of these concentra-
tions, the samples each generated the same amount of kallikrein (Fig 2A) and also the same
amount of bradykinin (Fig 2B) as each other. As with the kallikrein generation assay, native
CSA and unfractionated heparin at 100μg/ml did not generate any bradykinin, with values
similar to background.
Antithrombin titration
The fluorescence of antithrombin shows a clear rise in signal when increasing levels of heparin
are added (Fig 3). Heparin, which binds to antithrombin with high affinity due to the presence
of the pentasacchairde sequence, induces a structural change in antithrombin which gives rise
Table 4. Amount of material required to generate an OD change of 0.2 in the kallikrein generation assay.
Sample μg
OSCS 6.0
Dextran Sulfate 25.0
Native CS >100
CS 2.4 34.0
CS 3.0 50.0
CS 3.1 36.0
CS 3.2 23.0
CS 4.0 6.0
CH 4.0 #2 5.0
Heparin >100
An estimation was made based on the amount of each material required to cause an OD change of 0.2 above baseline,
as shown in Fig 1 inset.
https://doi.org/10.1371/journal.pone.0193482.t004
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to an increase in fluorescence [20]. No oversulfated chondroitin samples were able to elicit a
clear increase in fluorescence response, which would indicate that the samples do not bind
with any specificity to antithrombin.
Discussion
Adulteration of heparin with chemically oversulfated chondroitin sulfate was the cause of a
contamination issue in 2007/8 [2]. In the current study di-, tri and tetra-sulfated chondroitin
Fig 2. Kallikrein and Bradykinin levels obtained from a defined quantity of synthetic and purified OSCS, native
chondroitin sulfate, dextran sulfate and unfractionated heparin. Different amounts of each material, predicted to
generate the same level of (A) kallikrein as determined by optical density increase and (B) bradykinin, were used (see
Table 4). No statistical difference was observed between the samples (oneway ANOVA, p = 0.883 and 0.568
respectively). CS-A and UFH were included at 100μg/ml, the highest level used. Error bars = standard deviation; n = 6.
https://doi.org/10.1371/journal.pone.0193482.g002
Fig 3. Antithrombin titration response for synthetic OSCS, native chondroitin sulfate and a heparin sample. The
increase in fluorescence (ex280nm em340nm) response measured from antithrombin with increasing concentrations
of each sample. Error bar is SD, n = 6.
https://doi.org/10.1371/journal.pone.0193482.g003
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sulfates were generated, and NMR and sulfate-to-carboxylate ratio analysis confirmed the
structures, with the two tetra-sulfate variants having similar structures to that seen in oversul-
fated chondroitin sulfate isolated from a sample of the contaminated heparin. In general, the
increase in sulfation paralleled a slight increase in molecular weight by both TDA and Broad
Standard method, however no increase was seen with CS3.0 to CS4.0 samples. The triple detec-
tor method gave higher number average molecular weight, Mn, and weight average molecular
weight, Mw, than the broad standard method, and this may be due to the use of an unfractio-
nated heparin sample as the calibrant in the broad standard method which may not provide an
accurate calibration for OSCS. Interestingly, the molecular weight observed for the purified
OSCS material is lower (Mw 15740 versus 21100 and 21750) than the two synthetic tetra-sul-
fated versions and is similar to a previous observation [21] for OSCS. This is likely due to dif-
ferences in the starting CS sample and /or ‘manufacturing’ process, in the same way that
unfractionated heparin from different manufacturers possess different molecular weights [22].
The ability of OSCS to act as an anticoagulant via prolongation of clotting times and poten-
tiation of thrombin inhibition in plasma has previously been shown in a limited way [9]. In the
present study we have measured the anticoagulant activity of fully and partially sulfated OSCS
samples relative to the International Standard for Unfractionated heparin, both in purified
and plasma-based assays. This is the first report where the specific activities of variably oversul-
fated chondroitin sulfate preparations have been determined precisely using validated pharma-
copoeial monograph assays and statistical methods. Previous studies have demonstrated
anticoagulant activity in plasma and in antithrombin based assays [7–9], but these have been
limited as they do not give specific activity, and in the case of plasma assays which showed the
presence of anticoagulant activity, but not specifically the mechanisms of this activity. Interest-
ingly all oversulfated samples were found to give statistically valid results, via the multiple dilu-
tion analysis method as defined by the European Pharmacopoeia [16]. This is an unusual
observation; compounds with such different modes of action compared with the reference
heparin standard do not as a rule give valid assays. Unlike heparin, the ability of OSCS samples
to bind antithrombin is very limited as shown by antithrombin fluorescence titration. Whilst
there is a gradual increase in fluorescence with increasing concentration of material this may
be a non-specific interaction.
The addition of extra sulfates to chondroitin sulfate increased the anticoagulant activity in
all assays, with some correlation between increasing sulfation and anticoagulant activity.
Whilst the addition of sulfates does increase the Mw of the samples, there was no noticeable
effect on the anticoagulant activity. Anticoagulant activity measured using plasma (both
human and sheep plasma) showed a clear increase based on sulfation, though beyond 3 sulfates
per disaccharide there was no difference seen in potency measured by plasma between any of
the synthetic samples. In the antithrombin mediated inhibition of activated factor X and
thrombin (Table 3), there is a clear increase in activity with additional sulfates, though these
activities are very low (<6 IU/mg). This low detectable activity in the presence of antithrombin
is non-specific since OSCS is not able to bind to antithrombin with high affinity as it does not
contain the essential pentasaccharide sequence (2). The activity was not due to direct inhibi-
tion of thrombin or factor Xa.
Several studies have indicated that dermatan sulfate, chondroitin sulfates and other polya-
nions (such as pentosan polysulfate, dextran sulfate) exhibit their anticoagulant activity inde-
pendent of antithrombin, and show that this is through heparin cofactor II [11, 23]. Our
results in a heparin cofactor II purified assay system, directly provides evidence that OSCS
inhibition of thrombin is via interaction with heparin cofactor II. A previous study using sur-
face plasmon resonance has shown that heparin cofactor II binds to OSCS, but this did not
show direct potentiation of heparin cofactor II inhibition of thrombin. Dermatan sulfate is
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considered the main potentiator of HCII in vivo [24], and the key sulfate locations are 2-O-sul-
fate on iduronic acid and 4-O-sulfate on N-acetylgalactosamine which are considered impor-
tant for binding and thrombin inhibition activity [25, 26]. These positions correspond to 2-O-
sulfate on glucuronic acid and the 4-O-sulfate on N-acetylgalactosamine in the over sulfated
chondroitin sulfate variants. The increase in 2-O-sulfatation on the glucuronic acid from
CS2.4 (5%) to CS3.0 (41%) supports this observation. Interestingly the tetra sulfated CS, fully
sulfated at positions 2 and 3 on glucuronic acid, gave a lower heparin cofactor II mediated
activity than the tri-sulfated CS samples. This lower heparin cofactor II mediated activity in
the tetra-sulfated CS could be due to ‘repulsive’ effects, possibly caused by the extra 3-O-sulfate
on glucuronic acid acting to limit heparin cofactor II binding. Alternatively, the extra sulfate
on glucuronic acid may cause some steric hinderance and changes to the conformation of CS
[7], thereby preventing the binding of OSCS to heparin co-factor II. In all the assays the chemi-
cally prepared tetra-sulfated CS behaves in a similar manner to OSCS purified from contami-
nated heparin, despite the slightly lower molecular weight.
The reduction in anticoagulant activity as measured by heparin cofactor II when sulfation
is increased from 3.0 to 4.0 is not observed with either the sheep or human plasma assays. In
both these assays there is no reduction in activity. There are some possible contributory factors
which may help to explain these differences. Whilst the activity shown by the antithrombin
assays is low, it is known that potentiation of antithrombin inhibition of thrombin is an order
of magnitude higher that potentiation of heparin cofactor II inhibition of thrombin [27]. A
key difference in the anticoagulant assays is the incubation times that the samples have to
potentiate the inhibition of thrombin and factor Xa. In the plasma assay thrombin and factor
Xa are generated in situ, whilst for the purified assays thrombin/factor Xa are added and the
residual activity measured. The incubation used in heparin cofactor II is much longer (seven
minutes) than in the antithrombin dependent assays (two and one minute, factor Xa and
thrombin respectively) and the plasma assays (three minutes). Therefore, the contributory
effect of heparin cofactor II may be more limited in the plasma assays. Furthermore, heparin-
antithrombin can inhibit other coagulation enzymes (factor XIa, factor IXa) [28] which are
upstream of factor Xa and thrombin, and may have a role in the plasma assay.
As previously reported [3] OSCS is capable of causing the activation of kallikrein in plasma,
though no concentration response was observed. Activation of kallikrein is confirmed by the
present study with purified OSCS from adulterated heparin and two chemically prepared tetra
sulfate chondroitin sulfates. All three materials were found to give a concentration dependent
response, which is similar to a previous report [21] on OSCS from contaminated heparin in a
prekallikrein assay. We have clearly shown that increasing the level of sulfation causes an
increase in the ability of CS to generate kallikrein. This is likely due to the increase in negative
charge by addition of sulfate groups, as in other negatively charged polysaccharides [29, 30]
such as dextran sulfate (as shown herein) can also activate prekallikrein. However, charge acti-
vation alone may not be sufficient to generate kallikrein since an unadulterated porcine hepa-
rin preparation which has similar sulfation to the di-sulfate CS, did not generate any
kallikrein. Furthermore, there were some subtle differences in response between CS3.0, CS3.1
and CS3.2 which could indicate that there may be some specific features that influence the acti-
vation of kallikrein. Previously it has been shown that OSCS can activate bradykinin [4, 31]
and this study under the conditions used the is no bradykinin activity without kallikrein for-
mation. Concentrations of OSCS that generated the same level of kallikrein, also generated the
same amount of bradykinin, consistent with prekallikrein activation being the sole mechanism
through which OSCS influences bradykinin generation. This suggests that none of the OSCS
samples can directly influence formation of bradykinin.
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Whilst increasing the level of O-sulfation in CS will increase the anti-IIa activity as previ-
ously reported [7], given the observed differences between the oversulfated CSs in the kalli-
krein assay, the results presented here suggest that there may be more subtle structural
interactions other than sulfation at play. Production of pure compounds with highly defined
patterns of sulfation would be needed to resolve these questions.
Conclusion
Herein we report the specific anticoagulant activities of differentially oversulfated chondroitin
sulfates for the first time. We further show how increased sulfation on chondroitin sulfate
results in an increase in activity in several different anticoagulant assay systems. Prekallikrein
activation was shown to be both concentration and broadly sulfation dependent.
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